Study Group: Physicians who Treat Depression (US)
Council Members in this Study Group: 448
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Ara Dikranian
Partner and Rheumatologist
San Diego Arthritis Medical Clinic
Ara Dikranian, MD, is Partner and Rheumatologist at San Diego Arthritis Medical Clinic, a single-specialty private practice in San Diego, California. Dr. Dikranian is board certified in internal medicine and rheumatology. He completed his rheumatology...
Daniel WynnDirector of Clinical Research
CONSULTANTS IN NEUROLOGY LTDDaniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple...
Marina RaikhelDirector
TORRANCE MEMORIAL MEDICAL CENTERMarina Raikhel, MD, is an active family practitioner with a particular interest in primary care and ob/gyn focus. She has expertise in the treatment of a wide variety of internal medicine conditions, with special focus on diabetes, hypertension, obesity,...
David PortmanDirector
COLUMBUS CENTER FOR WOMENS HEALTH RESEARCHDavid Portman, MD, is Director and Principal Investigator of the Columbus Center for Women's Health Research. Dr. Portman is also a Clincial Investigator at The Ohio State University. He has conducted over 100 clinical studies in areas of contraception,...
- David Rosenberg
Chief of Psychiatry and Psychology
CHILDREN'S HOSPITAL OF MICHIGANDavid Rosenberg, MD, is a tenured professor and Miriam L Hamburger Endowed Chair of Psychiatry at Wayne State University and the Children's Hospital of Michigan. He is a board certified general and adult psychiatrist and pediatric psychiatrist. Dr. Rosenberg...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Fampridine-SR -- anxiously awaited new MS therapeutic
June 2, 2009
Analysis by: Daniel Wynn, Director of Clinical Research,Acorda’s Fampridine-SR Gets Priority Review | phoenix.corporate-ir.net
A major unmet need in the treatment of Multiple Sclerosis is a medication to increase walking ability. Since disease modifying therapies have only been available for 16 years, MS starts at a mean age of 29, and the disease has only a minimal effect at shortening lifespan, the majority of MS patients presently have progressive forms of MS. Ten percent have primary progressive disease, progressive from the onset, and others, start with relapsing remitting MS, and progress after approximately 15 years to progressive illness. In the early years of progressive MS, patients loose the ability to walk, hence the prior motto of the National MS Society, "MS, the great crippler of young adults." FAMPRIDINE SR IS THE FIRST MEDICATION FOUND TO IMPROVE MS PATIENTS ABILITY TO WALK. Standard disease modifying agents, the interferons (Avonex, Betaseron, Rebif), Copaxone and Tysabri, decrease relapse rate and may slow progression, however do not improve one's ability to walk.
-
NUVIGIL for Jet Lag -- An Important Broad New Indication for Cephalon
June 2, 2009
Analysis by: Daniel Wynn, Director of Clinical Research,Cephalon to apply for FDA approval for Nuvigil for jet lag | www.reuters.com
NUVIGIL, Cephalon's single isomer longer effective half-life follow-up product to Provigil is coming to market only after careful strategic planning. While extremely successful, Provigil, a unique wake promoting agent, suffered in many ways. When introduced, it had only FDA approval for narcolepsy, a relatively uncommon, yet severe sleep disorder. Sales increased markedly when Provigil became approved for other common conditions associated with excessive daytime sleepiness (EDS), treated obstructive sleep apnea with residual EDS and sleep wake shift disturbance (SWSD). If approved for Jet Lag, there is the promise that Nuvigil will become available for an increasing enlarging marketplace.
-
"Tamper-Proof" -- A Significant Gain to Whom??
November 17, 2008
Analysis by: Daniel Wynn, Director of Clinical Research,FDA Asks if Pain Pill Is Tamper-Proof | online.wsj.com
Abuse resistant long acting narcotics offer benefit as they are less desirable to those who might wish a quick high via snorting, injecting crushed time-release narcotic. Unfortunately, given the higher cost than long acting generics and increased pressure on physicians to prescribe generics, expect pick up in the marketplace (assuming approval) to be slow.
-
Novartis and Multiple Sclerosis: A Major Commitment
June 5, 2008
Analysis by: Daniel Wynn, Director of Clinical Research,Extavia® approved in E.U for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis | www.asia-manufacturing.com
Extavia, Novartis' brand of interferon beta 1b, has been approved for the treatment of multiple sclerosis by the European Union. With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009. While essentially identical to Bayer's Betaferon interferon beta 1b, and similar to EMD Serono's Rebif and Biogen's Avonex, Extavia does not offer a new therapy to MS patients, simply a new face. With this launch, Novartis presumably hopes to work closer to key opinion leaders in multiple sclerosis, allowing an accelerated launch of Fingolimod.
-
Abbott's ABT-089 --Much More than a Treatment for ADHD
June 2, 2008
Analysis by: Daniel Wynn, Director of Clinical Research,Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD. The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.
Members in this Study Group include these company types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Owner
- Physician - Director
- President
- Director
- Medical Director
- Physician - Division Head
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| SSRI Prescribers (US) | 279 |
| Psychiatrists (US) | 1136 |
| Psychiatrists | 1535 |
| Physicians who Treat Insomnia (US) | 546 |
| Physicians who Treat ADHD (US) | 453 |
| Physicians who Treat Schizophrenia (US) | 364 |
| Ambien Prescribers (US) | 319 |
| Lunesta Prescribers (US) | 277 |